These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4029012)

  • 1. Effect of renal function and dialysis on temocillin pharmacokinetics.
    Boelaert J; Daneels R; Schurgers M; Mellows G; Swaisland AJ; Lambert AM; Van Landuyt HW
    Drugs; 1985; 29 Suppl 5():109-13. PubMed ID: 4029012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of temocillin in patients with normal and impaired renal function.
    Boelaert J; Daneels R; Schurgers M; Lambert AM; Van Landuyt HW; Mellows G; Wolf J; Swaisland AJ
    J Antimicrob Chemother; 1983 Apr; 11(4):349-56. PubMed ID: 6853404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temocillin pharmacokinetics in normal and impaired renal function.
    Höffler D; Koeppe P
    Drugs; 1985; 29 Suppl 5():135-9. PubMed ID: 4029017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.
    Vandecasteele SJ; Miranda Bastos AC; Capron A; Spinewine A; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2015 Dec; 46(6):660-5. PubMed ID: 26603304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of mezlocillin during haemodialysis.
    Thorsteinsson SB; Steingrimsson O; Asmundsson P; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():59-63. PubMed ID: 6458883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
    Lameire N; Rosenkranz B; Malerczyk V; Lehr KH; Veys N; Ringoir S
    Clin Pharmacokinet; 1991 Nov; 21(5):357-71. PubMed ID: 1773550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure.
    Watson ID; Boulton-Jones M; Stewart MJ; Henderson I; Payton CD
    Ther Drug Monit; 1987 Jun; 9(2):139-47. PubMed ID: 3617151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
    Browning MJ; Holt HA; White LO; Chapman ST; Banks RA; Reeves DS; Yates RA
    J Antimicrob Chemother; 1986 Jul; 18(1):103-6. PubMed ID: 3463556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temocillin elimination in patients with varying degrees of renal failure.
    Wright N; Wise R; Price JD
    J Antimicrob Chemother; 1983 May; 11(5):481-4. PubMed ID: 6874633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of temocillin in volunteers.
    Hampel B; Feike M; Koeppe P; Lode H
    Drugs; 1985; 29 Suppl 5():99-102. PubMed ID: 4029032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
    Donnelly PK; Burwell N; McBurney A; Ward JW; Walls J; Watkin EM
    Br J Radiol; 1992 Dec; 65(780):1108-13. PubMed ID: 1286420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.